TG Therapeutics Inc (TGTX)

Days of sales outstanding (DSO)

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Receivables turnover		2.27	4.07	4.31	4.35	4.60	1.08	0.73	—	—	79.10	8.76	4.82	3.18	2.59	1.18	—	—	—	—	—
DSO	days	161.00	89.60	84.63	83.87	79.34	338.10	497.14	—	—	4.61	41.66	75.79	114.65	140.77	310.27	—	—	—	—	—

September 30, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.27
= 161.00

The Days Sales Outstanding (DSO) metric for TG Therapeutics Inc has shown significant fluctuations over the past few quarters. In the most recent period, as of September 30, 2024, the DSO stood at 161.00 days, indicating that on average, it takes the company approximately 161 days to collect its accounts receivable.

Comparing this to the previous quarters, there is a notable increase from June 30, 2024, where the DSO was 89.60 days. This suggests a potential deterioration in the company's accounts receivable collection efficiency. However, it is important to note that the DSO has historically shown variability, with previous peaks such as 497.14 days on March 31, 2023, and 338.10 days on June 30, 2023.

The DSO of 4.61 days reported on March 31, 2022, points to an exceptionally efficient collection period, showcasing a stark contrast to the higher DSO figures in other periods. This highlights fluctuations in the company's collection practices or possibly changes in its customer base.

Overall, the trend in TG Therapeutics Inc's DSO warrants further investigation into the company's accounts receivable management and credit policies to assess the impact of these fluctuations on its financial performance and liquidity position.